1. Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter’s Transformation
- Author
-
Valentín Ortiz-Maldonado, Gerard Frigola, Marta Español-Rego, Olga Balagué, Nuria Martínez-Cibrián, Laura Magnano, Eva Giné, Mariona Pascal, Juan G. Correa, Alexandra Martínez-Roca, Joan Cid, Miquel Lozano, Neus Villamor, Daniel Benítez-Ribas, Jordi Esteve, Armando López-Guillermo, Elías Campo, Álvaro Urbano-Ispizua, Manel Juan, and Julio Delgado
- Subjects
CLL ,CART ,CD19 ,DLBCL ,Richter disease ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
CART19 cells are emerging as an alternative therapy for patients with chronic lymphocytic leukemia (CLL). Here we report the outcome of nine consecutive patients with CLL treated with ARI-0001 CART19 cells, six of them with Richter’s transformation (RT). One patient with RT never received therapy. The cytokine release syndrome rate was 87.5% (12.5% grade ≥3). Neurotoxicity was not observed in any patient. All patients experienced absolute B-cell aplasia, and seven (87.5%) responded to therapy. With a median follow-up of 5.6 months, two patients with RT experienced a CD19-negative relapse. In conclusion, ARI-0001 cell therapy was feasible, safe, and effective in patients with high-risk CLL or RT.
- Published
- 2022
- Full Text
- View/download PDF